Your browser doesn't support javascript.
loading
Antiviral innate immunity is diminished in the upper respiratory tract of severe COVID-19 patients.
Ramos-Benitez, Marcos J; Strich, Jeffrey R; Alehashemi, Sara; Stein, Sydney; Rastegar, Andre; de Jesus, Adriana Almeida; Bhuyan, Farzana; Ramelli, Sabrina; Babyak, Ashley; Perez-Valencia, Luis; Vannella, Kevin M; Grubbs, Gabrielle; Khurana, Surender; Gross, Robin; Hadley, Kyra; Liang, Janie; Mazur, Steven; Postnikova, Elena; Warner, Seth; Holbrook, Michael R; Busch, Lindsay M; Warner, Blake; Applefeld, Willard; Warner, Sarah; Kadri, Sameer S; Davey, Richard T; Goldbach-Mansky, Raphaela; Chertow, Daniel S.
Afiliación
  • Ramos-Benitez MJ; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.
  • Strich JR; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Alehashemi S; Postdoctoral Research Associate Training Program, National Institute of General Medical Sciences, Bethesda, MD 20892.
  • Stein S; Ponce Health Science University and Ponce Research Institute, Department of Basic Sciences, School of Medicine, Ponce, Puerto Rico, USA.
  • Rastegar A; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.
  • de Jesus AA; The United States Public Health Service Commissioned Corps, Rockville, MD, USA.
  • Bhuyan F; Translational Autoinflammatory Diseases Section (TADS), Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy, and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
  • Ramelli S; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.
  • Babyak A; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Perez-Valencia L; Translational Autoinflammatory Diseases Section (TADS), Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy, and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
  • Vannella KM; Translational Autoinflammatory Diseases Section (TADS), Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy, and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
  • Grubbs G; Translational Autoinflammatory Diseases Section (TADS), Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy, and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
  • Khurana S; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.
  • Gross R; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.
  • Hadley K; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Liang J; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.
  • Mazur S; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Postnikova E; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.
  • Warner S; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Holbrook MR; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD.
  • Busch LM; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD.
  • Warner B; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD.
  • Applefeld W; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD.
  • Warner S; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD.
  • Kadri SS; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD.
  • Davey RT; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD.
  • Goldbach-Mansky R; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.
  • Chertow DS; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD.
medRxiv ; 2022 Nov 13.
Article en En | MEDLINE | ID: mdl-36415460
ABSTRACT
Understanding early innate immune responses to coronavirus disease 2019 (COVID-19) is crucial to developing targeted therapies to mitigate disease severity. Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection elicits interferon expression leading to transcription of IFN-stimulated genes (ISGs) to control viral replication and spread. SARS-CoV-2 infection also elicits NF-κB signaling which regulates inflammatory cytokine expression contributing to viral control and likely disease severity. Few studies have simultaneously characterized these two components of innate immunity to COVID-19. We designed a study to characterize the expression of interferon alpha-2 (IFNA2) and interferon beta-1 (IFNB1), both type-1 interferons (IFN-1), interferon-gamma (IFNG), a type-2 interferon (IFN-2), ISGs, and NF-κB response genes in the upper respiratory tract (URT) of patients with mild (outpatient) versus severe (hospitalized) COVID-19. Further, we characterized the weekly dynamics of these responses in the upper and lower respiratory tracts (LRTs) and blood of severe patients to evaluate for compartmental differences. We observed significantly increased ISG and NF-κB responses in the URT of mild compared with severe patients early during illness. This pattern was associated with increased IFNA2 and IFNG expression in the URT of mild patients, a trend toward increased IFNB1-expression and significantly increased STING/IRF3/cGAS expression in the URT of severe patients. Our by-week across-compartment analysis in severe patients revealed significantly higher ISG responses in the blood compared with the URT and LRT of these patients during the first week of illness, despite significantly lower expression of IFNA2, IFNB1, and IFNG in blood. NF-κB responses, however, were significantly elevated in the LRT compared with the URT and blood of severe patients during peak illness (week 2). Our data support that severe COVID-19 is associated with impaired interferon signaling in the URT during early illness and robust pro-inflammatory responses in the LRT during peak illness.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: MedRxiv Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: MedRxiv Año: 2022 Tipo del documento: Article